Spots Global Cancer Trial Database for antisense
Every month we try and update this database with for antisense cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors | NCT00636545 | Solid Tumors | Oblimersen (Gen... Oblimersen (Gen... | 18 Years - | Genta Incorporated | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Study of XIAP Antisense for Advanced Cancers | NCT00385775 | Advanced Cancer | AEG35156 | 18 Years - | Aegera Therapeutics | |
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | NCT01018069 | Leukemia | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML | NCT00363974 | Leukemia, Myelo... | XIAP antisense | 18 Years - | Aegera Therapeutics | |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT00882869 | Advanced Hepato... | AEG35156 antise... Sorafenib | 18 Years - | Aegera Therapeutics | |
| Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer | NCT00487786 | Neoplasms | OGX-427 Docetaxel | 18 Years - | Achieve Life Sciences | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | NCT00518895 | Melanoma | dacarbazine plu... dacarbazine plu... | 18 Years - | Genta Incorporated | |
| Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | NCT00078234 | Chronic Lymphoc... | Oblimersen-ritu... | 18 Years - | Genta Incorporated | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer | NCT00558545 | Human Mammary C... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer | NCT00100672 | Neoplasms | LErafAON-ETU | 18 Years - | INSYS Therapeutics Inc | |
| Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer | NCT00100672 | Neoplasms | LErafAON-ETU | 18 Years - | INSYS Therapeutics Inc | |
| A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases | NCT01120288 | Neoplasms Liver Metastase... | EZN-2968 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | NCT00518895 | Melanoma | dacarbazine plu... dacarbazine plu... | 18 Years - | Genta Incorporated | |
| Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer | NCT00487786 | Neoplasms | OGX-427 Docetaxel | 18 Years - | Achieve Life Sciences | |
| Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | NCT00074737 | Acute Myelogeno... | cenersen Idarubicin Cytarabine | 18 Years - | Eleos, Inc. | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT00882869 | Advanced Hepato... | AEG35156 antise... Sorafenib | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | NCT00074737 | Acute Myelogeno... | cenersen Idarubicin Cytarabine | 18 Years - | Eleos, Inc. | |
| Study of XIAP Antisense for Advanced Cancers | NCT00385775 | Advanced Cancer | AEG35156 | 18 Years - | Aegera Therapeutics | |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT00882869 | Advanced Hepato... | AEG35156 antise... Sorafenib | 18 Years - | Aegera Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
